Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

FATE – Fate Therapeutics, Inc.

Fate Therapeutics, Inc.
FATE
$1.90
Name : Fate Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $221,462,448.00
EPSttm : -1.09
finviz dynamic chart for FATE
Fate Therapeutics, Inc.
$1.90
0.52%
$0.01
FATE — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

8.8

Margin Of Safety %

Put/Call OI Ratio

0.15

EPS Next Q Diff

EPS Last/This Y

0.11

EPS This/Next Y

0.12

Price

1.89

Target Price

5.41

Analyst Recom

1.91

Performance Q

47.29

Upside

-1,362.1%

Beta

2.58

Ticker: FATE




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-05-11FATE2.170.110.0110476
2026-05-12FATE2.240.110.0110364
2026-05-13FATE2.130.100.0311199
2026-05-14FATE1.90.110.0610635
2026-05-15FATE1.750.110.0110770
2026-05-18FATE1.740.170.014150
2026-05-19FATE1.880.140.035015
2026-05-20FATE1.8350.120.005949
2026-05-21FATE2.110.111.056134
2026-05-22FATE2.240.140.116637
2026-05-26FATE2.140.150.036828
2026-05-27FATE2.360.150.096777
2026-05-28FATE2.620.140.066849
2026-05-29FATE2.840.140.297236
2026-06-02FATE2.560.200.005932
2026-06-03FATE2.20.190.076197
2026-06-04FATE2.20.190.036336
2026-06-05FATE1.980.160.157381
2026-06-08FATE1.90.150.017620
2026-06-09FATE1.90.150.407739
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-05-11FATE2.1814.1- -1.13
2026-05-12FATE2.2414.1- -1.13
2026-05-13FATE2.1314.1- -1.13
2026-05-14FATE1.9114.1- -1.13
2026-05-15FATE1.7614.1- -1.13
2026-05-18FATE1.7414.1- -1.13
2026-05-19FATE1.8914.1- -1.13
2026-05-20FATE1.8311.0- -0.99
2026-05-21FATE2.1111.0- -0.99
2026-05-22FATE2.2410.9- -1.00
2026-05-26FATE2.1411.2- -1.04
2026-05-27FATE2.3611.2- -1.04
2026-05-28FATE2.6211.2- -1.04
2026-05-29FATE2.8411.2- -1.04
2026-06-01FATE2.7311.2- -1.04
2026-06-02FATE2.5611.2- -1.04
2026-06-03FATE2.1911.2- -1.04
2026-06-04FATE2.2011.2- -1.04
2026-06-05FATE1.9711.2- -1.04
2026-06-08FATE1.9011.2- -1.04
2026-06-09FATE1.8911.2- -1.04
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-05-11FATE-0.26-0.039.33
2026-05-12FATE-0.25-0.039.32
2026-05-13FATE-0.25-0.039.32
2026-05-14FATE-0.25-0.039.32
2026-05-15FATE-0.25-0.039.26
2026-05-18FATE-0.2910.199.23
2026-05-19FATE-0.2910.199.23
2026-05-20FATE-0.2910.199.23
2026-05-21FATE-1.2610.199.23
2026-05-22FATE-1.2610.199.23
2026-05-26FATE-1.2611.919.28
2026-05-27FATE-1.1511.919.28
2026-05-28FATE-1.1511.918.80
2026-05-29FATE-1.1511.918.80
2026-06-02FATE-1.1511.298.80
2026-06-03FATE-1.1511.298.80
2026-06-04FATE-1.1511.298.80
2026-06-05FATE-1.1511.298.80
2026-06-08FATE-1.1511.308.80
2026-06-09FATE-1.1511.308.80
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.26

Avg. EPS Est. Current Quarter

-0.26

Avg. EPS Est. Next Quarter

-0.26

Insider Transactions

-1.15

Institutional Transactions

11.3

Beta

2.58

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

1

Fair Value

Quality Score

12

Growth Score

31

Sentiment Score

9

Actual DrawDown %

98.1

Max Drawdown 5-Year %

-99.3

Target Price

5.41

P/E

Forward P/E

PEG

P/S

35.04

P/B

1.23

P/Free Cash Flow

EPS

-1.09

Average EPS Est. Cur. Y​

-1.04

EPS Next Y. (Est.)

-0.92

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-2056.79

Relative Volume

0.68

Return on Equity vs Sector %

-99.8

Return on Equity vs Industry %

-83.6

EPS 1 7Days Diff

EPS 1 30Days Diff

0.1

EBIT Estimation

FATE Healthcare
$1.90
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
2/20
Pullback
23/25
Volume
6/15
Valuation
10/20
TP/AR
1/10
Options
8/10
RSI
45.3
Range 1M
24%
Sup Dist
1.4%
🚀
Momentum Growth
Ride accelerating trends
N/A
30 /100
WEAK
Momentum
2/25
Growth
11/30
Estimates
0/20
Inst/Vol
9/15
Options
8/10
EPS Yr
6.4%
EPS NY
9.7%
52W%
50.3%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +184.7% upside
Quality
2/30
Valuation
16/30
Growth
8/25
Stability
7/10
LT Trend
0/5
Upside
+184.7%
Quality
12
Fate Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 161
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
FATE

Latest News

Caricamento notizie per FATE
stock quote shares FATE – Fate Therapeutics, Inc. Stock Price stock today
news today FATE – Fate Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch FATE – Fate Therapeutics, Inc. yahoo finance google finance
stock history FATE – Fate Therapeutics, Inc. invest stock market
stock prices FATE premarket after hours
ticker FATE fair value insiders trading